$NSRX News
Last published 1mo ago
- 1mo agoNSRXNOMURA (NYSE: NMR) RINGS THE CLOSING BELL® - NASUS PHARMA LTDEarnings Call TranscriptsThank you. Thank you. Thank you. All right. Thank you. Thank you. Thank you. Thank you.
- 1mo agoNSRXNasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of AnaphylaxisGlobeNewswireClinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to
- 2mo agoNSRXNasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireTEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development
- 2mo agoNSRXTHE GRAND OPENING OF NYSE TEXAS HEADQUARTERS IN DALLAS! - NASUS PHARMA LTDEarnings Call Transcriptsyou you you you you you you you you you you you you you you you Transcription by CastingWords Thank you. Thank you. Thank you. Oh, all right. All right, so thank you all for being here today. 127, NYSE, Texas, listed com
- 2mo agoNSRXNasus Pharma Announces Transition of Chief Financial OfficerGlobeNewswireTEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development
- 2mo agoNSRXNasus Pharma Reports First Half 2026 Financial Results and Provides Business UpdateGlobeNewswireAppointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nasus
- 3mo agoNSRXASRTNasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic GrowthGlobeNewswireTEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development
- 4mo agoNSRXNasus Pharma to Participate in the Zacks Life Sciences Investor ForumGlobeNewswireTEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative
- 5mo agoNSRXNasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)GlobeNewswireStudy Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study in Third Quarter of
- 5mo agoNSRXNasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of AnaphylaxisGlobeNewswireTEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products,
- 6mo agoNSRXNasus Pharma to Participate in Upcoming Investor ConferencesGlobeNewswireTEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative
- 7mo agoNSRXNasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business UpdateGlobeNewswireRecent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4
- 8mo agoNSRXNasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic ThresholdGlobeNewswireNS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects
- 8mo agoNSRXNasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical StudyGlobeNewswireTEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal
- 8mo agoNSRXNasus Pharma to Present and Participate in the Upcoming Life Sciences Investor ForumGlobeNewswireTEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal
- 8mo agoNSRXNasus Pharma to Participate in Upcoming Investor ConferencesGlobeNewswireTEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal
- 8mo agoNSRXNasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026GlobeNewswireTEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal
- 9mo agoNSRXNasus Pharma Announces Closing of $15.0 Million Private PlacementGlobeNewswireTEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal
- 9mo agoNSRXNasus Pharma Announces Pricing of $15.0 Million Private PlacementGlobeNewswireTEL AVIV, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative
- 9mo agoNSRXNasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine PowderGlobeNewswireInterim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen® 91% of study participants achieved the 100 pg/ml plasma threshold at 5 minutes
- 10mo agoNSRXNasus Pharma CEO Issues 2025 Letter to ShareholdersGlobeNewswireTEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of
- 11mo agoNSRXNasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial OfficerGlobeNewswireTEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative
- 11mo agoNSRXNasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant DosedGlobeNewswireThe Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can achieve faster and
- 1y agoNSRXNasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine PowderGlobeNewswireTEL AVIV, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat
- 1y agoNSRXNasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine ProgramGlobeNewswireTEL AVIV, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat
- 1y agoNSRXNasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireTEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products
- 1y agoNSRXNasus Pharma Marks NYSE American Listing with Bell Ringing CeremonyGlobeNewswireTEL AVIV, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products
- 1y agoNSRXNasus Pharma Announces Closing of Initial Public OfferingGlobeNewswireTEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products
- 1y agoNSRXNasus Pharma Announces Pricing of $10 Million Initial Public OfferingGlobeNewswireTEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products